Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
18. Juli 2024 09:00 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces First Quarter 2024 Financial Results and Business Update
14. Mai 2024 07:00 ET
|
https://immatics.com/
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily...
Immatics Announces Full Year 2023 Financial Results and Corporate Update
21. März 2024 07:00 ET
|
https://immatics.com/
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median...
Immatics Announces Pricing of $175 Million Public Offering
17. Januar 2024 20:30 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Proposed Public Offering
17. Januar 2024 16:01 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Third Quarter 2023 Financial Results and Business Update
14. November 2023 07:00 ET
|
https://immatics.com/
ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including...
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
08. November 2023 07:00 ET
|
https://immatics.com/
Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for...
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
24. Oktober 2023 07:00 ET
|
https://immatics.com/
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer typesRegulatory activities...
Moderna und Immatics geben strategische Multi-Plattform-Kollaboration zur Entwicklung innovativer Onkologie Therapeutika bekannt
11. September 2023 07:00 ET
|
Immatics N.V.
Kollaboration kombiniert führende Technologien zur Entwicklung bahnbrechender, in vivo exprimierter mRNA TCER®-MoleküleDie Unternehmen werden zur Entwicklung neuartiger Krebsimpfstoffe Immatics...
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
11. September 2023 07:00 ET
|
https://immatics.com/
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® moleculesCompanies to leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s...